HK1214169A1 - 用於治療癌症的瑞戈非尼和乙酰水楊酸的組合 - Google Patents

用於治療癌症的瑞戈非尼和乙酰水楊酸的組合

Info

Publication number
HK1214169A1
HK1214169A1 HK16102326.3A HK16102326A HK1214169A1 HK 1214169 A1 HK1214169 A1 HK 1214169A1 HK 16102326 A HK16102326 A HK 16102326A HK 1214169 A1 HK1214169 A1 HK 1214169A1
Authority
HK
Hong Kong
Prior art keywords
regorafenib
combination
treating cancer
acetylsalicylic acid
acetylsalicylic
Prior art date
Application number
HK16102326.3A
Other languages
English (en)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1214169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1214169A1 publication Critical patent/HK1214169A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16102326.3A 2012-09-25 2016-03-01 用於治療癌症的瑞戈非尼和乙酰水楊酸的組合 HK1214169A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (1)

Publication Number Publication Date
HK1214169A1 true HK1214169A1 (zh) 2016-07-22

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102326.3A HK1214169A1 (zh) 2012-09-25 2016-03-01 用於治療癌症的瑞戈非尼和乙酰水楊酸的組合

Country Status (29)

Country Link
US (1) US10898500B2 (zh)
EP (1) EP2900269B1 (zh)
JP (1) JP6294888B2 (zh)
KR (1) KR102210575B1 (zh)
CN (1) CN104994876A (zh)
AU (1) AU2013322854B2 (zh)
BR (1) BR112015006686B1 (zh)
CA (1) CA2885688C (zh)
CL (1) CL2015000744A1 (zh)
CY (1) CY1120939T1 (zh)
DK (1) DK2900269T3 (zh)
EA (1) EA032023B1 (zh)
ES (1) ES2687985T3 (zh)
HK (1) HK1214169A1 (zh)
HR (1) HRP20181462T1 (zh)
HU (1) HUE039878T2 (zh)
IL (1) IL237690B (zh)
LT (1) LT2900269T (zh)
MX (1) MX357035B (zh)
MY (1) MY183969A (zh)
NZ (1) NZ705860A (zh)
PH (1) PH12015500587A1 (zh)
PL (1) PL2900269T3 (zh)
PT (1) PT2900269T (zh)
RS (1) RS57875B1 (zh)
SG (2) SG11201501963RA (zh)
SI (1) SI2900269T1 (zh)
WO (1) WO2014048881A1 (zh)
ZA (1) ZA201502840B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
HUE036117T2 (hu) 2013-11-26 2018-06-28 Hoffmann La Roche Oktahidro-ciklobuta[1,2-C;3,4-C']dipirrol származékok, mint autotaxin inhibitorok
CN106029667B (zh) 2014-03-26 2019-08-23 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CN117982446A (zh) * 2016-06-28 2024-05-07 阿萨德股份有限公司 双组分组合物
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PT3630112T (pt) 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002014A1 (fr) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Compositions medicamenteuses destinees au traitement du cancer colorectal
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8637553B2 (en) * 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2628881A1 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
SG11201501963RA (en) 2015-04-29
CY1120939T1 (el) 2019-12-11
EA032023B1 (ru) 2019-03-29
JP6294888B2 (ja) 2018-03-14
DK2900269T3 (en) 2018-10-01
JP2015529234A (ja) 2015-10-05
KR20150060869A (ko) 2015-06-03
RS57875B1 (sr) 2018-12-31
US10898500B2 (en) 2021-01-26
US20150202214A1 (en) 2015-07-23
CL2015000744A1 (es) 2016-01-08
PT2900269T (pt) 2018-10-22
NZ705860A (en) 2018-07-27
BR112015006686B1 (pt) 2022-04-05
EP2900269B1 (en) 2018-08-01
PL2900269T3 (pl) 2019-02-28
KR102210575B1 (ko) 2021-02-02
LT2900269T (lt) 2018-11-12
AU2013322854B2 (en) 2018-07-19
MX357035B (es) 2018-06-25
AU2013322854A1 (en) 2015-04-02
HRP20181462T1 (hr) 2018-11-02
PH12015500587A1 (en) 2015-05-11
CA2885688C (en) 2021-03-02
CA2885688A1 (en) 2014-04-03
MX2015003728A (es) 2015-09-23
MY183969A (en) 2021-03-17
SG10201702356VA (en) 2017-04-27
WO2014048881A1 (en) 2014-04-03
HUE039878T2 (hu) 2019-02-28
SI2900269T1 (sl) 2018-10-30
EA201500365A1 (ru) 2015-08-31
ZA201502840B (en) 2017-11-29
CN104994876A (zh) 2015-10-21
IL237690A0 (en) 2015-05-31
EP2900269A1 (en) 2015-08-05
IL237690B (en) 2019-07-31
BR112015006686A2 (pt) 2019-08-27
ES2687985T3 (es) 2018-10-30

Similar Documents

Publication Publication Date Title
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
PT2818482T (pt) Composição farmacêutica para o tratamento de cancro
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
HUE045461T2 (hu) Gyógyászati készítmény rák kezelésére
PL2740796T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740794T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2903644A4 (en) TREATMENT OF CANCER
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
EP2817011A4 (en) TREATMENT OF CANCER
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
GB201217890D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201208296D0 (en) Treatment of cancer